Angiopoietin-like protein 2 is an important facilitator of tumor proliferation, metastasis, angiogenesis and glycolysis in osteosarcoma.

Xiuhui Wang, Zhaohui Hu, Zhe Wang, Yin Cui, Xu CuiPubMed 2019

TL;DR

This study reveals that Angiopoietin-like protein 2 (Angptl2) is significantly upregulated in osteosarcoma (OS) cells under hypoxic conditions, driven by Hypoxia-Inducible Factor 1-alpha (HIF-1α). Angptl2 appears to be a key facilitator of OS progression, promoting tumor growth, metastasis, angiogenesis, and glycolysis, suggesting it could be a valuable biomarker for predicting patient survival.

What Problem Does This Paper Address?

Osteosarcoma (OS) is a highly aggressive bone cancer, particularly in adolescents, characterized by rapid progression and poor prognosis. While the tumor microenvironment, especially hypoxia (low oxygen), is known to drive malignant behaviors like proliferation and metastasis, the specific molecular mechanisms are not fully understood. Hypoxia-Inducible Factor 1-alpha (HIF-1α) is a master regulator activated by hypoxia, influencing numerous genes. Angiopoietin-like protein 2 (Angptl2) is a known hypoxia-inducible gene, but its precise role and the relationship between Angptl2 and hypoxia in OS remained unclear. This paper aims to elucidate this relationship and investigate Angptl2's contribution to OS progression.

Methods

The researchers employed a multi-pronged approach to investigate Angptl2's role in OS:

  • Cell Culture and Hypoxia Simulation: Human OS cell lines were cultured under both normal (5% O₂) and hypoxic (2.5% O₂) conditions to mimic the tumor microenvironment.
  • Molecular Expression Analysis:
    • Western Blotting: Used to quantify protein levels of Angptl2, HIF-1α, and various downstream effectors (e.g., CDK2, cyclin E1, p21, MMP2, MMP9, VEGFA, Ang II, HK2).
  • Quantitative RT-PCR (qRT-PCR): Used to measure mRNA levels of Angptl2 and HIF-1α.
  • Functional Assays (In Vitro):
    • Cell Viability: Assessed using the CCK-8 assay.
  • Cell Cycle Analysis: Performed using flow cytometry.
  • Cell Invasion and Migration: Evaluated using Transwell and Scratch assays, respectively.
  • Glycolysis Assessment: Measured glucose consumption and lactate production using specific kits.
  • Genetic Manipulation:
    • Overexpression: Angptl2 was overexpressed in OS cells to study its effects.
  • siRNA Knockdown: HIF-1α was silenced using siRNA to investigate its role in Angptl2 regulation.
  • Pharmacological Inhibition: The glycolysis inhibitor 2-DG was used to probe the role of glycolysis.
  • In Vivo Studies:
    • Xenograft Models: OS cells with Angptl2 overexpression were injected into nude mice to assess tumor growth.
  • Immunohistochemistry and Immunofluorescence: Used to detect protein expression (Angptl2, Ki-67) in tumor tissues.

Datasets

Not explicitly detailed as separate datasets. The study utilized established human osteosarcoma cell lines (MG63, MHM, HOS-143B, U2OS, and OSA) obtained from the American Type Culture Collection. In vivo experiments utilized female BALB/c nude mice.

Key Insights and Ideas

  • Hypoxia as a Driver of Angptl2: The study strongly links hypoxia to increased Angptl2 expression in OS cells, mediated by HIF-1α. This highlights a critical pathway by which the tumor microenvironment promotes aggressive behavior.
  • Angptl2 as a Multifaceted Promoter of OS: Angptl2 isn't just a passive marker; it actively drives multiple hallmarks of cancer progression:
  • Proliferation: It pushes cells through the cell cycle and increases expression of key cell cycle regulators (CDK2, cyclin E1).
  • Metastasis: It enhances cell migration and invasion, partly by upregulating matrix metalloproteinases (MMPs).
  • Angiogenesis: It promotes the formation of new blood vessels by increasing VEGFA and Ang II.
  • Glycolysis: It fuels the Warburg effect by increasing glucose uptake and lactate production, likely through HK2.
  • Potential as a Biomarker: The consistent upregulation of Angptl2 in aggressive OS and its role in multiple pro-tumorigenic pathways suggest it could serve as a valuable prognostic marker for patient survival.

Key Results

  • Angptl2 and HIF-1α expression were significantly increased in OS cells under hypoxic conditions (2.5% O₂) compared to normoxic conditions (5% O₂).
  • Overexpression of Angptl2 significantly increased OS cell proliferation, promoted G1/S phase transition, and reduced p21 expression while increasing CDK2 and cyclin E1.
  • Angptl2 overexpression dramatically enhanced cell migration and invasion, correlating with increased MMP2 and MMP9 expression.
  • Angptl2 overexpression led to increased VEGFA and Ang II expression, indicative of enhanced angiogenesis.
  • Angptl2 overexpression facilitated glucose consumption and lactate production, suggesting enhanced glycolysis, and this was linked to increased HK2 expression.
  • In vivo, Angptl2 overexpression significantly promoted OS tumor growth and increased tumor weight in xenograft models, with higher Ki-67 proliferation marker expression.
  • Silencing HIF-1α reduced Angptl2 expression, confirming HIF-1α's role in its induction.

Limitations and Future Work

  • Mechanism Complexity: While the study identifies Angptl2 as a key player, the intricate signaling pathways through which Angptl2 exerts its effects require further exploration. The authors suggest more experiments are needed to fully understand these pathways.
  • Biomarker Validation: While Angptl2 shows promise as a biomarker, further clinical validation in larger patient cohorts would be necessary to confirm its predictive value for long-term survival.
  • Therapeutic Targeting: The study lays the groundwork for exploring Angptl2 as a therapeutic target. Future work could focus on developing strategies to inhibit Angptl2 or its downstream pathways to combat OS.

Summary updated

Abstract

<i>Background:</i> Solid tumors are often exposed to hypoxia. Hypoxia inducible factor (HIF-1α) upregulates numerous target genes associated with the malignant behavior of hypoxic cancer cells. Angiopoietin-like protein 2 (Angptl2), a member of the angiopoietin family, is a hypoxia-inducible gene. However, the role and potential mechanism of Angptl2, and the relationship between Angptl2 and hypoxia in osteosarcoma (OS) remain unclear. <i>Methods:</i> In this study, quantitative RT-PCR was performed to detect the levels of Angptl2 and HIF-1α, and western blot assay was performed to measure the expression of Angptl2, HIF-1α, CDK2, cyclin E1, P21, MMP2, MMP9, VEGFA, Ang II and HK2 in osteosarcoma cells and tissue. Subsequently, cell viability and cycle were analyzed using CCK-8 and flow cytometer assays. Cell migration, invasion and glycolysis were analyzed with Transwell, Scratch Test and glucose/lactic acid detection kits, respectively. Experiments <i>in vivo</i> were performed to value the effects of Angptl2 on the growth of osteosarcoma xenografts in mice. Immunofluorescent and immunohistochemistry staining were conducted to detect the expression of Ki-67 and Angptl2, respectively. <i>Results:</i> The results demonstrated that Angptl2 was highly expressed in OS cells, which was induced by hypoxia (HIF-1α). Additionally, Angptl2 overexpression regulated cell proliferation, invasion, migration and G1 phase arrest in OS cells. Moreover, Angptl2 promoted OS tumor growth in vivo tumor xenografts. Angptl2 might enhance angiogenesis and glycolysis by promoting VEGFA, Ang II and HK2 both in vitro and in vivo. <i>Conclusion:</i> In conclusion, the present findings indicated that hypoxia-induced Angptl2 expression was independent of HIF-1α in hypoxic OS cells. Angptl2 might promote OS cell proliferation, metastasis, angiogenesis and glycolysis, which could be regarded as a favorable marker for predicting a long survival time in patients with OS.
BibTeX
@inproceedings{wang2019angiopoietin,
  author = {Xiuhui Wang and Zhaohui Hu and Zhe Wang and Yin Cui and Xu Cui},
  title = {{Angiopoietin-like protein 2 is an important facilitator of tumor proliferation, metastasis, angiogenesis and glycolysis in osteosarcoma.}},
  booktitle = {PubMed},
  year = {2019},
}
Figure